Overview of telomerase RNA component gene hTerc Transcriptional Regulation
Telomerase is an enzyme which replicates the terminal sequences of eukaryotic chromosomes, namely the telomeres. Cells which have an unlimited replicative capacity such as male germ cells and the majority of human cancers have high levels of telomerase activity. The level and frequency of telomerase activity in more than 85% of all cancers highlights the critical role telomerase plays in tumor progression. Telomerase activation is the most common general marker for a cancer cell to date making it an attractive target for new cancer diagnostics and therapeutics. Human telomerase activity can be reconstituted in vitro by the essential RNA subunit, hTERC, and the catalytic protein component coded for by the hTERT gene. Both the human telomerase reverse transcriptase gene (hTERT) and the telomerase RNA gene (hTERC) are controlled at least in part at the transcriptional level. The hTERC gene is expressed at high levels in cancer cells, and is absent or at low levels in some normal tissues.
Contributor:
REFERENCES: Abdul-Ghani R, Ohana P, Matouk I, Ayesh S, Ayesh B, Laster M, Bibi O, Giladi H, Molnar-Kimber K, Sughayer MA, de Groot N, Hochberg A. Use of Transcriptional Regulatory Sequences of Telomerase (hTER and hTERT) for Selective Killing of Cancer Cells. Mol Ther 2000; 2:539-544. Heine B, Hummel M, Demel G, Stein H. Demonstration of constant upregulation of the telomerase RNA component in human gastric carcinomas using in situ hybridization. Journal Of Pathology 1998; 185:139-44. Hiyama T, Yokozaki H, Kitadai Y, Haruma K, Yasui W, Kajiyama G, Tahara E. Overexpression of human telomerase RNA is an early event in oesophageal carcinogenesis. Virchows Arch 1999; 434:483-7. Hoare SF, Bryce LA, Wisman GB, Burns S, Going JJ, van der Zee AG, Keith WN. Lack of telomerase RNA gene hTERC expression in alternative lengthening of telomeres cells is associated with methylation of the hTERC promoter. Cancer Res 2001; 61:27-32. Sarvesvaran J, Going JJ, Milroy R, Kaye SB, Keith WN. Is small cell lung cancer the perfect target for anti-telomerase treatment? Carcinogenesis 1999; 20:1649-51. Shay JW, Zou Y, Hiyama E, Wright WE. Telomerase and cancer. Hum Mol Genet 2001; 10:677-85. Soder AI, Going JJ, Kaye SB, Keith WN. Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization. Oncogene 1998; 16:979-83 Soder AI, Hoare SF, Muir S, Going JJ, Parkinson EK, Keith WN. Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer. Oncogene 1997; 14:1013-21. White LK, Wright WE, Shay JW. Telomerase inhibitors. Trends Biotechnol 2001; 19:114-20. Wisman GB, De Jong S, Meersma GJ, Helder MN, Hollema H, De Vries EG, Keith WN, Van Der Zee AG. Telomerase in (pre)neoplastic cervical disease. Hum Pathol 2000; 31:1304-12. Yashima K, Maitra A, Rogers BB, Timmons CF, Rathi A, Pinar H, Wright WE, Shay JW, Gazdar AF. Expression of the RNA component of telomerase during human development and differentiation. Cell Growth And Differentiation 1998; 9:805-13 Yi X, Tesmer VM, Savre-Train I, Shay JW, Wright WE. Both transcriptional and posttranscriptional mechanisms regulate human telomerase template RNA levels. Molecular And Cellular Biology 1999; Zhao JQ, Glasspool RM, Hoare SF, Bilsland A, Szatmari II, Keith WN. Activation of Telomerase RNA Gene Promoter Activity by NF-Y, Sp1, and the Retinoblastoma Protein and Repression by Sp3. Neoplasia 2000; 2:531-539. Zhao JQ, Glasspool RM, Hoare SF, Bilsland A, Szatmari II, Keith WN. Activation of Telomerase RNA Gene Promoter Activity by NF-Y, Sp1, and the Retinoblastoma Protein and Repression by Sp3. Neoplasia 2000; 2:531-539.:1345-50. Zhao JQ, Hoare SF, McFarlane R, Muir S, Parkinson EK, Black DM, Keith WN. Cloning and characterization of human and mouse telomerase RNA gene promoter sequences. Oncogene 1998; 16:1345-50. Zhao JQ, Hoare SF, McFarlane R, Muir S, Parkinson EK, Black DM, Keith WN. Cloning and characterization of human and mouse telomerase RNA gene promoter sequences. Oncogene 1998; 1619:3989-97.
